Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amphastar Pharma

AMPH stock has doubled so far this year and is in a buy zone again. It earlier bought Eli Lilly's emergency diabetes drug which can drive future growth.

Will Eli Lilly's Emergency Diabetes Drug Give Amphastar Wings?

Is Eli Lilly stock a buy or a sell as shares seesaw in the wake of new Zepbound test results? LLY stock a buy or a sell right now?

Is Eli Lilly Stock A Buy Or A Sell As Shares Seesaw On Recent Obesity Drug Findings?

Novo Nordisk

Altimmune

Amgen

Structure Therapeutics Inc

Roche Holding AG

Viking Therapeutics

The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.

Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?

Pinduoduo Inc - ADR

Eli Lilly's sales growth should accelerate next year now that Zepbound has obtained approval. PDD Holdings owns Temu, which is one of the most popular e-commerce sites in the world today.

2 Unstoppable Growth Stocks to Buy in 2024

Novo Nordisk is the developer behind Ozempic and Wegovy, both of which are seeing unprecedented demand. Eli Lilly's Mounjaro is challenging the competition, generating over $3 billion in sales since its launch last May.

These 2 Unstoppable Stocks Could Make You Richer in 2024 and Beyond

Wall Street turned its focus to a handful of newer treatments in different disease areas in 2023, including weight loss medications and a new Alzheimer's drug.

Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma

Enbridge

Mastercard

Eli Lilly increased its dividend payments by 15% annually over three consecutive years. Mastercard boosted its rate of dividend increase this month as its business continues to do well.

3 Top Dividend Stocks That Recently Hiked Their Payouts

Pfizer

Pfizer has underperformed compared to Eli Lilly in recent years, but now appears to be a more attractive investment with fewer risks. Pfizer is more diversified, while Eli Lilly is heavily dependent on a single drug, making it riskier. Pfizer is priced for disaster and offers a higher dividend yield, making it a better investment option than Eli Lilly.

Eli Lilly Looks Overvalued, Buy Pfizer Instead

Weight-loss drug excitement went overboard in 2023. Novo Nordisk's Wegovy – which is known as Ozempic when used to treat diabetes – and Eli Lilly's Zepbound are the first effective treatments for obesity.

Ozempic overshoot will plump up bargain-hunters

GlaxoSmithKline

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.

5 Big Drug Stocks That May Continue to Outperform in 2024

Understanding what's hot and what's not is key to investing in biopharma. Drugs like Ozempic are going to continue being very popular next year.

These Are the 3 Hottest Biopharma Trends of 2024. Should You Invest?

Organon & Co

JERSEY CITY, N.J.--(BUSINESS WIRE) Organon becomes the sole distributor and promoter of Emgality® (galcanezumab) and RAYVOW™ (lasmiditan) in Europe.

Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines

Point Biopharma Global

INDIANAPOLIS , Dec. 18, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to expire at 5:00 p.m.

Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023

2024 will be another big year for weight loss drugs, which soared in popularity despite hefty price tags, mixed insurance coverage and unpleasant side effects.

The weight loss drug boom isn't over yet — here's what to expect in the year ahead

A recent study found that patients who quit taking Lilly's Zepbound regain much of their weight. Investors viewed this as bad news for Lilly, but it's actually good news.

Patients Regain Weight After They Quit Using Ozempic Rival Zepbound. Here's Why That Makes Eli Lilly Stock an Even Better Buy.

Advanced Micro Devices

ASML Hld

LVMH Moet Hennessy Louis Vuitton

UnitedHealth Group

Visa

The magnificent seven stocks have had a fantastic 2023. Those firms dominate Silicon Valley and are amongst seven of the largest eight firms globally, as measured by market capitalization.

The New Magnificent 7: 7 Stocks Rising to Prominence

Merck

Health care stocks to check out in the stock market now.

What Are The Best Stocks To Invest In Now? 2 Health Care Stocks To Watch

Full results from a late-stage study show that patients who stopped taking Eli Lilly's (LLY) weight-loss drug for over a year slowly started to regain their lost weight.

LLY Down as Patients Regain Weight After Stopping Zepbound

Weight loss drugs are expected to be some of the best-selling pharma products of all time by 2030. Eli Lilly and Novo Nordisk are the frontrunners in this space.

Better Weight Loss Stock: Eli Lilly or Novo Nordisk?

INDIANAPOLIS , Dec. 11, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated clinical data from the international Phase 1/2 BRUIN trial of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, in adult patients with a range of B-cell malignancies. These data, which were presented in oral and poster presentations at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, continue to support the role of pirtobrutinib in the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL).

Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting

Eli Lilly (LLY) shares fell 2.3% Monday after a study conducted by the drug maker found patients who use its weight-loss treatments may gain weight once they stop taking the drugs.

Eli Lilly Stock Slips After Reported Weight Gain In Users Who Quit Its Drug

Patients using Eli Lilly's weight-loss drug Zepbound experienced a “substantial regain” of lost weight after withdrawing from treatment, according to a study published Monday, the latest study indicating withdrawal from weight-loss drugs could cause patients to regain lost weight.

Patients Who Stopped Using Zepbound Experienced ‘Substantial' Weight Regain, Eli Lily's Study Suggests

The data suggests that people have to stay on the weekly injection Zepbound if they want to maintain weight loss.

Patients regain weight after stopping Eli Lilly's Zepbound, study says

A JAMA study shows that patients who stopped taking Zepbound after 36 weeks on the drug experienced a 14% weight regain over a year.

Eli Lilly Stock Falls on Data That Show Patients Who Stopped Zepbound Regained Weight

Cigna

Humana

U.S. equities were little changed at midday ahead of key inflation data due later in the week and the final Federal Reserve policy meeting of 2023. The Dow and S&P 500 were up slightly, while the Nasdaq was in the red.

News for Eli Lilly Stock (LLY)